Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacology of inhaled polymyxin B for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia
ChiCTR2400080344Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jan 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polymyxin B in Acinetobacter baumannii pneumonia, sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: clinical efficacy. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
polymyxin B
03
Conditions
Acinetobacter baumannii pneumonia
Beyond the preview
Go deeper on ChiCTR2400080344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080344.